I suppose your question is one for the BOD and management. That is, are the results that positive on efficacy, that a pivot in strategy is in the shareholders best interests? You seem to think so which is great.
I still think PAR needs to clarify the pivot. IMHO, the lack of interest in a deal on the P2 data is material to the SP.
I suppose your question is one for the BOD and management. That...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
-0.005(2.04%) |
Mkt cap ! $83.95M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 25.0¢ | 24.0¢ | $161.8K | 659.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 153650 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 24634 | 1 |
View Market Depth
| Last trade - 16.10pm 11/06/2024 (20 minute delay) ? |
|
|||||
|
Last
24.3¢ |
Change
-0.005 ( 3.00 %) |
||||
| Open | High | Low | Volume | ||
| 25.0¢ | 25.0¢ | 24.3¢ | 213542 | ||
| Last updated 15.59pm 11/06/2024 ? | |||||
| PAR (ASX) Chart |